Lipid receptor SR-B1 identified as a potential immunotherapy target to boost NK cell antitumor response in advanced ovarian cancer.

New research led by Irish scientists has uncovered how lipid-rich fluid in the abdomen, known as ascites, plays a central ...

New research led by Irish scientists has uncovered how lipid-rich fluid in the abdomen, known as ascites, plays a central ...

A Ludwig Cancer Research study has identified a key mechanism by which advanced ovarian cancers suppress anti-tumor immune ...

Explore Fate Therapeutics' pipeline, financials, and market position to assess if its 75% drop reflects true value or ...

Zelluna (OSE: ZLNA), a company pioneering allogeneic 'off the shelf' T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, announces its first quarter ...

New research led by Irish scientists has added “a critical piece to the puzzle” of the aggressiveness of ovarian cancer.

BOCA RATON, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company”), a clinical-stage ...

A global study suggests that using small molecule inhibitors followed by epigenetic modifiers may significantly improve ...

How your immune system really ages — research shows aging brings adaptation not decline and reveals ways to maintain immune ...